Current understanding of Alzheimer’s disease and other neurodegenerative diseases, and the potential role of diet and lifestyle in reducing the risks of Alzheimer’s disease and cognitive decline

Author Identifier

Warnakulasuriya Fernando

https://orcid.org/0000-0002-8364-7808

Document Type

Book Chapter

Publication Title

Neurodegeneration and Alzheimer's disease: The role of diabetes, genetics, hormones, and lifestyle

Publisher

Wiley

School

School of Medical and Health Sciences / Centre of Excellence for Alzheimer's Disease Research and Care

RAS ID

36927

Comments

Brennan, C. S., Brennan, M. A., Fernando, W. M. A. D. B., & Martins, R. N. (2019). Current understanding of Alzheimer’s disease and other neurodegenerative diseases, and the potential role of diet and lifestyle in reducing the risks of Alzheimer’s disease and cognitive decline. In R. N. Martins, C. S. Brennan, W. M. A. D. B. Fernando, M. A. Brennan & S. J. Fuller (Eds.), Neurodegeneration and Alzheimer's disease: The role of diabetes, genetics, hormones, and lifestyle (pp. 1-8). John Wiley & Sons Ltd. https://doi.org/10.1002/9781119356752.ch1

Abstract

This chapter presents an overview of key concepts covered in the subsequent chapters of this book. The book is intended to give an up-to-date overview of what is currently known about neurodegenerative diseases, focusing particularly on Alzheimer's disease (AD). Current and developing diagnostic tests are described, and the pathological relationships between AD and other conditions now believed to be risk factors for AD are also described. In particular, the book discusses cardiovascular disease, obesity, insulin resistance and type 2 diabetes, focusing on abnormal lipid and sugar metabolism linked to these conditions, and how this is related to AD risk. It provides evidence that improved diet and exercise may reduce AD risk, not just the risk of the other conditions mentioned above. Hopefully the book provides some food for thought concerning easily adoptable non-pharmacological methods to reduce AD risk, which would need to be adopted at early pre-clinical stages of the disease.

Access Rights

subscription content

Link to Full Text

Share

 
COinS